Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Antigen-based vaccination and prevention of type 1 diabetes.

Harrison LC, Wentworth JM, Zhang Y, Bandala-Sanchez E, Böhmer RM, Neale AM, Stone NL, Naselli G, Bosco JJ, Auyeung P, Rashidi M, Augstein P, Morahan G.

Curr Diab Rep. 2013 Oct;13(5):616-23. doi: 10.1007/s11892-013-0415-7. Review.

PMID:
23888323
2.
3.

Autoimmune diabetes: the role of T cells, MHC molecules and autoantigens.

Durinovic-Belló I.

Autoimmunity. 1998;27(3):159-77. Review.

PMID:
9609134
4.

The prospect of vaccination to prevent type 1 diabetes.

Harrison LC.

Hum Vaccin. 2005 Jul-Aug;1(4):143-50. Epub 2005 Jul 18. Review.

PMID:
17012869
5.

An oral vaccine for type 1 diabetes based on live attenuated Salmonella.

Husseiny MI, Rawson J, Kaye A, Nair I, Todorov I, Hensel M, Kandeel F, Ferreri K.

Vaccine. 2014 Apr 25;32(20):2300-7. doi: 10.1016/j.vaccine.2014.02.070. Epub 2014 Mar 12.

PMID:
24631074
6.

Parameters influencing antigen-specific immunotherapy for type 1 diabetes.

Wang B, Tisch R.

Immunol Res. 2008;41(3):175-87. doi: 10.1007/s12026-008-8020-6.

PMID:
18543112
7.

Translating mucosal antigen based prevention of autoimmune diabetes to human.

Bonifacio E, Ziegler A, Achenbach P, Barker J, Eisenbarth G.

Novartis Found Symp. 2008;292:187-99; discussion 199-201, 202-3.

PMID:
19203100
8.

Vaccination against self to prevent autoimmune disease: the type 1 diabetes model.

Harrison LC.

Immunol Cell Biol. 2008 Feb;86(2):139-45. doi: 10.1038/sj.icb.7100151. Epub 2008 Jan 8. Review.

PMID:
18180798
10.

Thymic self-antigens for the design of a negative/tolerogenic self-vaccination against type 1 diabetes.

Geenen V, Mottet M, Dardenne O, Kermani H, Martens H, Francois JM, Galleni M, Hober D, Rahmouni S, Moutschen M.

Curr Opin Pharmacol. 2010 Aug;10(4):461-72. doi: 10.1016/j.coph.2010.04.005. Epub 2010 Apr 29. Review.

PMID:
20434402
11.

Immunotherapy trials for type 1 diabetes: the contribution of George Eisenbarth.

Skyler JS, Pugliese A.

Diabetes Technol Ther. 2013 Jun;15 Suppl 2:S2-13-S2-20. doi: 10.1089/dia.2013.0107.

12.
13.

Characterization of antibody responses to endogenous and exogenous antigen in the nonobese diabetic mouse.

Koczwara K, Schenker M, Schmid S, Kredel K, Ziegler AG, Bonifacio E.

Clin Immunol. 2003 Feb;106(2):155-62.

PMID:
12672406
14.

Insulin as a key autoantigen in the development of type 1 diabetes.

Nakayama M.

Diabetes Metab Res Rev. 2011 Nov;27(8):773-7. doi: 10.1002/dmrr.1250. Review.

15.

Parameters influencing antigen-specific immunotherapy for Type 1 diabetes.

Wang B, Tisch R.

Immunol Res. 2008;42(1-3):246-58. doi: 10.1007/s12026-008-8090-5.

PMID:
19052699
16.

Genetic and therapeutic control of diabetogenic CD8+ T cells.

Santamaria P.

Novartis Found Symp. 2008;292:130-6; discussion 136-45, 202-3.

PMID:
19209463
17.
18.

Protective role of anti-idiotypic antibodies in autoimmunity--lessons for type 1 diabetes.

Hampe CS.

Autoimmunity. 2012 Jun;45(4):320-31. doi: 10.3109/08916934.2012.659299. Epub 2012 Feb 23. Review.

19.

Isolation of nonobese diabetic mouse T-cells that recognize novel autoantigens involved in the early events of diabetes.

Gelber C, Paborsky L, Singer S, McAteer D, Tisch R, Jolicoeur C, Buelow R, McDevitt H, Fathman CG.

Diabetes. 1994 Jan;43(1):33-9.

PMID:
8262314
20.

Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading.

Prasad S, Kohm AP, McMahon JS, Luo X, Miller SD.

J Autoimmun. 2012 Dec;39(4):347-53. doi: 10.1016/j.jaut.2012.04.005. Epub 2012 May 28.

Supplemental Content

Support Center